StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)

Close on Nov 17, 2026Market cap $226.53MP/E –Yield –

Arcturus Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Arcturus Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$102.30M. For fiscal 2025 it was -$76.26M. The highest annual figure on record is $12.18M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.26M–
FY2024Dec 31, 2024-$95.67M–
FY2023Dec 31, 2023-$78.21M-742.2%
FY2022Dec 31, 2022$12.18M–
FY2021Dec 31, 2021-$202.85M–
FY2020Dec 31, 2020-$71.52M–
FY2019Dec 31, 2019-$25.51M–
FY2018Dec 31, 2018-$21.81M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$25.55M–
Q1 FY2026Mar 31, 2026-$28.93M–
Q4 FY2025Dec 31, 2025-$31.31M–
Q3 FY2025Sep 30, 2025-$16.51M–
Q2 FY2025Jun 30, 2025-$11.62M–
Q1 FY2025Mar 31, 2025-$16.83M–
Q4 FY2024Dec 31, 2024-$33.39M–
Q3 FY2024Sep 30, 2024-$10.74M–
Q2 FY2024Jun 30, 2024-$21.13M–
Q1 FY2024Mar 31, 2024-$30.41M-306.1%
Q4 FY2023Dec 31, 2023-$18.27M-115.0%
Q3 FY2023Sep 30, 2023-$19.31M–
Q2 FY2023Jun 30, 2023-$55.37M–
Q1 FY2023Mar 31, 2023$14.76M–
Q4 FY2022Dec 31, 2022$121.45M–
Q3 FY2022Sep 30, 2022-$36.81M–
Q2 FY2022Jun 30, 2022-$22.09M–
Q1 FY2022Mar 31, 2022-$50.38M–
Q4 FY2021Dec 31, 2021-$37.65M–
Q3 FY2021Sep 30, 2021-$53.82M–
Q2 FY2021Jun 30, 2021-$53.72M–
Q1 FY2021Mar 31, 2021-$57.67M–
Q4 FY2020Dec 31, 2020-$31.08M–
Q3 FY2020Sep 30, 2020-$20.94M–
Q2 FY2020Jun 30, 2020-$10.04M–
Q1 FY2020Mar 31, 2020-$9.46M–
Q4 FY2019Dec 31, 2019-$10.82M–
Q3 FY2019Sep 30, 2019-$7.62M–
Q2 FY2019Jun 30, 2019-$572.00K–
Q1 FY2019Mar 31, 2019-$6.51M–
Q4 FY2018Dec 31, 2018-$711.00K–
Q3 FY2018Sep 30, 2018-$4.36M–
Q2 FY2018Jun 30, 2018-$10.07M–

More Arcturus Therapeutics figures

See a number that looks wrong?